October 18, 2007 - The American College of Radiology (ACR) recently reported that the recent Annual Report to the Nation on the Status of Cancer credits improved screening techniques and more effective treatment for the noticeable drop in national cancer mortality rates.
Recently, the ACR launched ACR Image Metrix, a contract research organization, which assists pharmaceutical and biotech manufacturers in the anticancer drug development using cutting-edge imaging to assist in the more rapid assessment of new anticancer compounds.
The ACR, through its clinical trials research groups, the American College of Radiology Imaging Network (ACRIN) and the Radiation Therapy Oncology Group (RTOG), has conducted research in diagnostic imaging and radiation therapy for almost 40 years and is one of the largest NCI funded clinical research organizations in the country.
The ACR’s clinical research programs are said to be among the largest recipients of federal medical research grants and have an established reputation for handling large-scale clinical trials, involving up to 50,000 patients and the processing of some 50 million images. ACR Image Metrix will reportedly leverage the same infrastructure and expertise, but will provide support to pharmaceutical companies, biotechnology firms and medical device manufacturers seeking Food and Drug Administration approval to bring new drugs, therapies, and medical devices to market.
For more information: www.imagemetrix.acr.org